The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update

The international, phase III, multi-centre AZA-001 trial demonstrated azacitidine (AZA) is the first treatment to significantly extend overall survival (OS) in higher risk myelodysplastic syndromes (MDS) patients (Fenaux (2007) Blood 110 817). The current treatment paradigm, which is based on a rela...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Silverman, LR, Fenaux, P, Mufti, GJ, Santini, V, Hellström-Lindberg, E, Gattermann, N, Sanz, G, List, AF, Gore, SD, Seymour, JF, Backstrom, J, McKenzie, D, Beach, CL
Formato: Artigo
Idioma:Inglês
Publicado em: Cancer Intelligence 2008
Assuntos:
Short Communications
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3234059/
https://ncbi.nlm.nih.gov/pubmed/22275990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2008.118
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados